New Treatments for Muscular Dystrophy
C2 domain therapeutics for muscular dystrophy
This research explores how a specific protein part, called the C2A domain, might help repair muscle damage and improve muscle function for people with certain types of muscular dystrophy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11146489 on NIH RePORTER |
What this research studies
Muscular dystrophies like Limb Girdle Muscular Dystrophy Type 2B and Miyoshi Myopathy happen when a protein called dysferlin doesn't work correctly. Dysferlin is essential for repairing muscle cell membranes and keeping calcium levels balanced, both critical for healthy muscle function. Our team discovered that a specific section of dysferlin, known as the C2A domain, plays a key role in these processes. We are now working to see if we can use a modified C2A domain, or a combination of C2A with another protein part, to restore these important functions in affected muscle cells. This work aims to develop new ways to treat these muscle conditions by directly addressing the protein's malfunction.
Who could benefit from this research
Good fit: This research is relevant for patients diagnosed with Limb Girdle Muscular Dystrophy Type 2B (LGMD 2B) or Miyoshi Myopathy (MMD1), as it directly addresses the genetic cause of their conditions.
Not a fit: Patients with muscular dystrophies not caused by dysferlin mutations may not directly benefit from this specific therapeutic approach.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that repair muscle damage and improve muscle function for individuals living with dysferlin-related muscular dystrophies.
How similar studies have performed: Initial findings from this team have shown promise for the C2A domain in laboratory settings, suggesting a novel and specific approach to restoring muscle function.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Bloch, Robert J — University of Maryland Baltimore
- Study coordinator: Bloch, Robert J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.